Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 892,520
  • Shares Outstanding, K 26,297
  • Annual Sales, $ 94,090 K
  • Annual Income, $ -31,290 K
  • 60-Month Beta 1.17
  • Price/Sales 9.56
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade CSTL with:

Options Overview Details

View History
  • Implied Volatility 74.09% ( +5.98%)
  • Historical Volatility 77.63%
  • IV Percentile 53%
  • IV Rank 27.06%
  • IV High 143.75% on 06/17/22
  • IV Low 48.25% on 08/02/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 897
  • Open Int (30-Day) 653

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.70
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.99
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -48.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.16 +44.60%
on 07/18/22
36.10 -7.22%
on 08/11/22
+8.76 (+35.42%)
since 07/15/22
3-Month
15.58 +114.96%
on 06/16/22
36.10 -7.22%
on 08/11/22
+13.78 (+69.91%)
since 05/13/22
52-Week
15.58 +114.96%
on 06/16/22
78.58 -57.38%
on 09/07/21
-30.95 (-48.03%)
since 08/13/21

Most Recent Stories

More News
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

CSTL : 33.49 (-1.33%)
SYRS : 1.0100 (+5.75%)
Castle Biosciences Reports Second Quarter 2022 Results

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June...

CSTL : 33.49 (-1.33%)
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CCCC : 12.13 (-1.38%)
CSTL : 33.49 (-1.33%)
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the American Gastroenterological Association (AGA) recently published...

CSTL : 33.49 (-1.33%)
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank...

CSTL : 33.49 (-1.33%)
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LUMO : 8.70 (+0.30%)
CSTL : 33.49 (-1.33%)
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CSTL : 33.49 (-1.33%)
INSM : 27.40 (+0.51%)
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and...

CSTL : 33.49 (-1.33%)
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s DecisionDx®-Melanoma gene...

CSTL : 33.49 (-1.33%)
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s...

CSTL : 33.49 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 35.13
2nd Resistance Point 34.60
1st Resistance Point 34.04
Last Price 33.49
1st Support Level 32.95
2nd Support Level 32.42
3rd Support Level 31.86

See More

52-Week High 78.58
Fibonacci 61.8% 54.52
Fibonacci 50% 47.08
Fibonacci 38.2% 39.65
Last Price 33.49
52-Week Low 15.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar